Management of anxiety disorders in children who survived the novel coronavirus infection
DOI: 10.32364/2618-8430-2022-5-4-340-345
G.R. Sagitova1, V.A. Shuldais2, N.V. Klyueva2, E.M. Shaforostova1, I.B. Konotopova2
1Astrakhan State Medical University, Astrakhan, Russian Federation
2Children’s City Polyclinic No.4, Astrakhan, Russian Federation
Background: currently, the term "post-COVID conditions" has been commonly used in healthcare practices. It includes impairments of multiple human organ systems. Many international and Russian researchers have mentioned in their studies that such patients, including children, are at a higher risk of developing psychoneurological disorders.
Aim: to assess the clinical efficacy of a syrup, containing choline, glycine, lysine, B vitamins, zinc, magnesium, lemon balm and mint extracts to cope with the manifestations of anxiety disorders developed in children after COVID-19 infection.
Patients and Methods: this prospective study involved 65 children, 7–11 years old, who had mild cases of COVID-19 and developed manifestations of anxiety disorders. All patients were given recommendations including nutritional therapy, sleep and rest routine, walking into the fresh air, and limiting the time children spend on their phones, computers and TV. 40 patients, 20 of whom were girls, of the treatment group (TG) additionally received a biologically active supplement (BAS), "Kidz Syrup with lemon balm and mint", at the dosage of 1 stick (5 ml) 3 times a day for 42 days. 25 children, 16 of whom were girls, were included in the control group (CG), receiving only routine treatment. The duration of follow-up period was 42 days. A questionnaire was filled out by children’s parents to assess the severity of asthenic syndrome.
Results: after one month of treatment with the BAS added to the routine therapy, the TG patients demonstrated trends in lower severity of all symptoms of asthenic syndrome vs that at the baseline (р<0.05, unpaired t-test). Such trends were not reported in the control group (р>0.05, unpaired t-test). Parents of the TG children reported more physical activity and interest, better sleep and appetite, normalizing kids’ behavior and improving relationships. In the CG patients, receiving routine therapy, these changes were less pronounced. Seven of 40 patients did not like taking the syrup because of the unpleasant syrup taste. It was the reason why three of 40 patients declined further participation in the study. None of the children reported allergic reactions.
Conclusion: a biologically active substance "Kidz syrup with lemon balm and mint" given to the primary school-aged children who survived COVID-19 and developed manifestations of anxiety disorders, helps to improve their ability to manage emotional distress, concentrate attention and memory, and has the protective effect against the increasing mental burdens.
Keywords: children, COVID-19, post-COVID conditions, anxiety disorders, biologically active supplement, lemon balm and mint.
For citation: Sagitova G.R., Shuldais V.A., Klyueva N.V. et al. Management of anxiety disorders in children who survived the novel coronavirus infection. Russian Journal of Woman and Child Health. 2022;5(4):340–345 (in Russ.). DOI: 10.32364/2618-8430-2022-5-4-340-345.
About the authors:
Gul’nara R. Sagitova — Dr. Sc. (Med.), Professor, Head of the Department of Inpatient Pediatrics with the course of post-graduate education, Astrakhan State Medical University; 121, Bakinskaya str., Astrakhan, 414000, Russian Federation; ORCID iD 0000-0002-8377-6212.
Vladimir A. Shuldais — Chief outsource nutritionist of the Ministry of health of Astrakhan Region; Chief Physician of Children’s City Polyclinic No.4; 66, bldn. 2, N. Ostrovsky str., Astrakhan, 414045, Russian Federation.
Nonna V. Klyueva — Head of the Breast-Feeding Center, Children’s City Polyclinic No.4; 66, bldn. 2, N. Ostrovsky str., Astrakhan, 414045, Russian Federation.
Elena M. Shaforostova — assistant of the Department of Inpatient Pediatrics with the course of post-graduate education, Astrakhan State Medical University; 121, Bakinskaya str., Astrakhan, 414000, Russian Federation; ORCID iD 0000-0002-0696-4690.
Irina B. Konotopova — pediatric neurologist, Children’s City Polyclinic No.4; 66, bldn. 2, N. Ostrovsky str., Astrakhan, 414045, Russian Federation.
Contact information: Elena M. Shaforostova, e-mail: lenchiknew@mail.ru.
Financial Disclosure: the research was supported by LLC VTF. No authors have a financial or property interest in any material or method mentioned.
There is no conflict of interests.
Received 14.09.2022.
Revised 07.10.2022.
Accepted 01.11.2022.
2. Liotto N., Miozzo M., Gianni M.L. et al. Early nutrition: the role of genetics and epigenetics. Pediatr Med Chir. 2009;31(2):65–71.
3. Heijmans B.T., Tobi E.W., Stein A.D. et al. Persistent epigenetic differences associated with prenatal exposure to famine in humans. PNAS USA. 2008;105(44):17046–17049. DOI: 10.1073/pnas.0806560105.
4. Захарова И.Н., Османов И.М., Творогова Т.М. и др. Постковидный синдром у детей в структуре COVID-19. Педиатрия. Consilium Medicum. 2022;1:8–14. DOI: 10.26442/26586630.2022.1.201515. [Zakharova I.N., Osmanov I.M., Tvorogova T.M. et al. Postcoid syndrome in children in the structure of COVID-19. Pediatrics. Consilium Medicum. 2022;1:8–14 (in Russ.)]. DOI: 10.26442/26586630.2022.1.201515.
5. Goërtz Y.M.J., van Herck M., Delbressine J.M. et al. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? ERJ Open Res. 2020;6(4):00542–2020. DOI: 10.1183/23120541.00542-2020.
6. Tenforde M.W., Kim S.S., Lindsell C.J. et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network — United States, March-June 2020. MMWR Morb Mortal Wkly Rep. 2020;69(30):993–998. DOI: 10.15585/mmwr.mm6930e1.
7. Hu B., Guo H., Zhou P., Shi Z.L. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19(3):141–154. DOI: 10.1038/s41579-020-00459-7.
8. Rubin R. As their numbers grow, COVID-19 "long haulers" stump experts. JAMA. 2020;324:1381–1383. DOI: 10.1001/jama.2020.17709.
9. Carfi A., Bernabei R., Landi F. Gemelli Against C-P-ACSG. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324(6):603–605. DOI: 10.1001/jama.2020.12603.
10. Mandal S., Barnett J., Brill S.E. et al.; ARC Study Group. ‘Long-COVID’: a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax. 2021;76(4):396–398. DOI: 10.1136/thoraxjnl-2020-215818.
11. Moghimi N., Di Napoli M., Biller. et al. The Neurological Manifestations of Post-Acute Sequelae of SARS-CoV-2 infection. Curr Neurol Neurosci Rep. 2021;21(9):44. DOI: 10.1007/s11910-021-01130-1.
12. Davis H.E., Assaf G.S., McCorkell L. et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38: 101019. DOI: 10.1101/2020.12.24.20248802.
13. Huang C., Huang L., Wang Y. et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397(10270):220–232. DOI: 10.1016/S0140-6736(20)32656-8.
14. Chopra V., Flanders S.A., O’Malley M. et al. Sixty-day outcomes among patients hospitalized with COVID-19. Ann Intern Med. 2021;174(4):576–578. DOI: 10.7326/ M20-5661.
15. Carvalho-Schneider C., Laurent E., Lemaignen A. et al. Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clin Microbiol Infect. 2021;27(2):258–263. DOI: 10.1016/j. cmi.2020.09.052.
16. Garrigues E., Janvier P., Kherabi Y. et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J Inf Secur. 2020;81(6):e4–6. DOI: 10.1016/j.jinf.2020.08.029.
17. Wortmann S.B., Mayr J.A. Choline-related-inherited metabolic diseases-A mini review. J Inherit Metab Dis. 2019;42(2):237–242. DOI: 10.1002/jimd.12011.
18. Pérez-Ràfols C., Liu Y., Wang Q. et al. Why Not Glycine Electrochemical Biosensors? Sensors (Basel). 2020;20(14):4049. DOI: 10.3390/s20144049.
19. Rowe E.M., Xing V., Biggar K.K. Lysine methylation: Implications in neurodegenerative disease. Brain Res. 2019;1707:164–171. DOI: 10.1016/j.brainres.2018.11.024.
20. Prasad AS. Zinc: role in immunity, oxidative stress and chronic inflammation. Curr Opin Clin Nutr Metab Care. 2009;12(6):646–52. DOI: 10.1097/MCO.0b013e3283312956.
21. Pal A., Squitti R., Picozza M. et al. Zinc and COVID-19: Basis of Current Clinical Trials. Biol Trace Elem Res. 2021;199(8):2882–2892. DOI: 10.1007/s12011-020-02437-9.
22. Munipalli B., Seim L., Dawson N.L. et al. Post-acute sequelae of COVID-19 (PASC): a meta-narrative review of pathophysiology, prevalence, and management. SN Compr Clin Med. 2022;4(1):90. DOI: 10.1007/s42399-022-01167-4.
23. Watkins L.E., Sprang K.R., Rothbaum B.O. Treating PTSD: a review of evidence-based psychotherapy interventions. Front Behav Neurosci. 2018;12:258. DOI: 10.3389/fnbeh.2018.00258.
24. Huang C., Huang L., Wang Y. et al. 6 month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397:220–232.
25. Carfi A., Bernabei R., Landi F. Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324(6):603–605.
26. Taquet M., Geddes J.R., Husain M. et al. 6-month neurological and psychiatric outcomes in 236379 survivors of COVID-19: a retrospective cohort научно- study using electronic health records. Lancet Psychiatry. 2021;8:416–427. DOI: 10.1016/S2215-0366(21)00084-5.
27. Иванова О.Н. Постковидный синдром у детей. Международный исследовательский журнал. 2021;111(9):35–39. [Ivanova O.N. Postcovid syndrome in children. International Research Journal. 2021;111(9):35–39 (in Russ.)].
This work is licensed under a Creative Commons «Attribution» 4.0 License.
